Post-Market BTVA Registry

Prior treatment

• Unstable COPD (any of the following):
  • \> 3 COPD related hospitalizations requiring antibiotics in past 12 months
  • COPD related hospitalization in past 3 months
  • daily use of systemic steroids, i.e. \> 5 mg prednisolone
• Concomitant illnesses or medications that would pose a significant increased risk for complications following treatment with InterVapor. Examples of particular relevance include: immune system disorders, immunosuppressant medications of clinical relevance, bleeding disorders and unstable cardiovascular conditions, history of asthma or alpha-1 antitrypsin deficiency

Other illness

• Recent respiratory infections or COPD exacerbation in preceding 6 weeks -

Lab values

• Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated white blood cell count)

Other

• FEV1 \< 20% predicted
• DLCO \< 20% predicted
• Inability to walk \> 140 meters in 6 minutes (6MWD) following optimized medical management
• Newly prescribed morphine derivatives within the last 4 weeks
• Pregnant or breastfeeding
• Highly diseased lower lobes (tissue to air ratio of \<11%)
• Presence of single large bulla (defined as \> 1/3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe

• Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index \> or equal to 1.2 in at least one segment to be treated
• Patients must be \> or equal to 18 years of age
• Patients are required to provide informed consent prior to inclusion in the Registry